Biomedical Engineering Reference
In-Depth Information
macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J
Med 351:657-67.
Jordan, C. T., Upchurch, D., Szilvassy, S. J., Guzman, M. L., Howard, D. S., Pettigrew, A. L.,
Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D. A., Luger, S. M. and Phillips, G. L. 2000.
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous
leukemia stem cells. Leukemia 14:1777-84.
Jorgensen, H. G., Allan, E. K., Jordanides, N. E., Mountford, J. C. and Holyoake, T. L. 2007.
Nilotinib exerts equipotent anti-proliferative effects to imatinib and does not induce
apoptosis in CD34+ CML cells. Blood 109:4016-9.
Kaeda, J., Chase, A. and Goldman, J. M. 2002. Cytogenetic and molecular monitoring of
residual disease in chronic myeloid leukaemia. Acta Haematol 107:64-75.
Kantarjian, H. M., Talpaz, M., Keating, M. J., Estey, E. H., O'Brien, S., Beran, M.,
McCredie, K. B., Gutterman, J. and Freireich, E. J. 1991. Intensive chemotherapy induc-
tion followed by interferon-alpha maintenance in patients with Philadelphia chromosome-
positive chronic myelogenous leukemia. Cancer 68:1201-7.
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C.,
Manley, P., Rae, P., Mietlowski, W., Bochinski, K., Hochhaus, A., Griffin, J. D., Hoelzer,
D., Albitar, M., Dugan, M., Cortes, J., Alland, L. and Ottmann, O. G. 2006. Nilotinib in
imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med
354:2542-51.
Kantarjian, H. M., O'Brien, S., Huang, X., Garcia-Manero, G., Ravandi, F., Cortes, J., Shan, J.,
Davisson, J., Bueso-Ramos, C. E. and Issa, J. P. 2007. Survival advantage with decitabine
versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: com-
parison with historical experience. Cancer 109:1133-7.
Kavalerchik, E., Gotlib, J., Geron, I., Abrahamsson, A., Wrasidlo, W., Goff, D., Lu, D.,
Molinsli, T., Giles, F., Weissman, I., Carson, D. and Jamieson, C. 2006. Inhibition of
chronic myelogenous leukemia stem cells with novel WNT antagonists. Blood 108:74a.
Kiel, M. J., Yilmaz, O. H., Iwashita, T., Yilmaz, O. H., Terhorst, C. and Morrison, S. J. 2005.
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal
endothelial niches for stem cells. Cell 121:1109-21.
Klein, U., Tu, Y., Stolovitzky, G. A., Mattioli, M., Cattoretti, G., Husson, H., Freedman, A.,
Inghirami, G., Cro, L., Baldini, L., Neri, A., Califano, A. and Dalla-Favera, R. 2001. Gene
expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous
phenotype related to memory B cells. J Exp Med 194:1625-38.
Kordes, U., Krappmann, D., Heissmeyer, V., Ludwig, W. D. and Scheidereit, C. 2000.
Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leuke-
mia cells. Leukemia 14:399-402.
Krivtsov, A. V. and Armstrong, S. A. 2007. MLL translocations, histone modifications and
leukaemia stem-cell development. Nat Rev Cancer 7:823-33.
Lajtha, L. G. 1979. Stem cell concepts. Differentiation 14:23-34.
Leary, A. G., Hirai, Y., Kishimoto, T., Clark, S. C. and Ogawa, M. 1989. Survival of
hemopoietic progenitors in the G0 period of the cell cycle does not require early hemo-
poietic regulators. Proc Natl Acad Sci USA 86:4535-8.
Leary, A. G., Zeng, H. Q., Clark, S. C. and Ogawa, M. 1992. Growth factor requirements for
survival in G0 and entry into the cell cycle of primitive human hemopoietic progenitors.
Proc Natl Acad Sci USA 89:4013-7.
Lessard, J. and Sauvageau, G. 2003. Bmi-1 determines the proliferative capacity of normal
and leukaemic stem cells. Nature 423:255-60.
Lugo, T. G., Pendergast, A. M., Muller, A. J. and Witte, O. N. 1990. Tyrosine kinase activity
and transformation potency of bcr-abl oncogene products. Science 247:1079-82.
Martin, P. J., Najfeld, V., Hansen, J. A., Penfold, G. K., Jacobson, R. J. and Fialkow, P. J.
1980. Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature
287:49-50.
